Mirum Pharmaceuticals (MIRM) Income from Continuing Operations (2019 - 2026)
Mirum Pharmaceuticals' (MIRM) quarterly Income from Continuing Operations came in at 790155000.0 in Q1 2026, down 5283.63% year-on-year from 15243282.98 in Q1 2025, and down 13689.79% quarter-over-quarter from 5730000.0 in Q4 2025.
Mirum Pharmaceuticals (MIRM) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Mirum Pharmaceuticals' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 790155000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 5283.63% year-over-year to 790155000.0 in Q1 2026; TTM through Mar 2026 was 798841000.0, a 932.9% decrease from a year earlier, with the FY2025 full-year figure at 23363000.0, up 73.43% from the prior year.
- Income from Continuing Operations fell to 790155000.0 in Q1 2026 per MIRM's latest filing, from 5730000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 2905000.0 in Q3 2025 and bottomed at 790155000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 25279000.0 (2024), against an average of 70620000.0.
- Across the five-year window, Income from Continuing Operations soared 120.41% in 2025 and sank 5283.63% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 36431000.0 in 2022, then increased by 2.12% to 35659000.0 in 2023, then surged by 33.28% to 23790000.0 in 2024, then soared by 75.91% to 5730000.0 in 2025, then slumped by 13689.79% to 790155000.0 in 2026.
- Per Business Quant, the three latest MIRM Income from Continuing Operations figures stand at 790155000.0 (Q1 2026), 5730000.0 (Q4 2025), and 2905000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Mirum Pharmaceuticals | 6.66 Bn | 6.27 Bn | 131.08 Mn | -790.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -790.16 Mn |
| Dec 31, 2025 | -5.73 Mn |
| Sep 30, 2025 | 2.91 Mn |
| Jun 30, 2025 | -5.86 Mn |
| Mar 31, 2025 | -14.68 Mn |
| Dec 31, 2024 | -23.79 Mn |
| Sep 30, 2024 | -14.24 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -25.28 Mn |
| Dec 31, 2023 | -35.66 Mn |
| Sep 30, 2023 | -23.59 Mn |
| Jun 30, 2023 | -74.04 Mn |
| Mar 31, 2023 | -30.13 Mn |
| Dec 31, 2022 | -36.43 Mn |
| Sep 30, 2022 | -35.71 Mn |
| Jun 30, 2022 | -26.92 Mn |
| Mar 31, 2022 | -36.61 Mn |
| Dec 31, 2021 | 57.28 Mn |
| Sep 30, 2021 | -47.11 Mn |
| Jun 30, 2021 | -43.89 Mn |